Esketamine
- Generic Name
- Esketamine
- Brand Names
- Spravato
- Drug Type
- Small Molecule
- Chemical Formula
- C13H16ClNO
- CAS Number
- 33643-46-8
- Unique Ingredient Identifier
- 50LFG02TXD
- Background
Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression.
...
- Indication
Esketamine is indicated in combination with an oral antidepressant for the treatment of treatment-resistant depression in adults. It is also indicated for the treatment of depressive symptoms in adults with major depressive disorder experiencing acute suicidal ideation or behaviour.
- Associated Conditions
- Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Pain
- Associated Therapies
- Intubation
Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI)
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 72
- Registration Number
- NCT04303325
- Locations
- 🇨🇳
the First Hospital of China Medical University, Shenyang, Liaoning, China
Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression
- Conditions
- Interventions
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 364
- Registration Number
- NCT03927378
- Locations
- 🇨🇳
Women's Hospital School Of Medicine Zhejiang University, Hanzhou, Zhejiang, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
🇨🇳Beijing Tiantan Hospital, Beijing, Beijing, China
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
- Conditions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT03829579
Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Göteborg University
- Target Recruit Count
- 220
- Registration Number
- NCT03756961
- Locations
- 🇸🇪
Lindesberg Hospital, Lindesberg, Region Örebro, Sweden
🇸🇪Sahlgrenska University hospital/ Östra hopsital, Gothenburg, VG, Sweden
Intranasal Esketamine and Fentanyl for Pain in Minor Trauma
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- Anna Meuronen, MD
- Target Recruit Count
- 105
- Registration Number
- NCT03421275
- Locations
- 🇫🇮
Hyvinkää Hospital, Hyvinkää, Finland
A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT03298906
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Use of S+Ketamine During Target-Controlled Intravenous Anaesthesia After Abdominal Hysterectomy
- Conditions
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- KK Women's and Children's Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT03231683
- Locations
- 🇸🇬
Kk Women'S and Children'S Hospital, Singapore, Singapore
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
- Conditions
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 147
- Registration Number
- NCT03185819
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Federico II, Napoli, Italy
🇫🇷Hopital Sainte Anne, Paris, France
🇮🇹OSP RIUNITI-DIP Donna- Bambino, Foggia, Italy
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
- Conditions
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 230
- Registration Number
- NCT03097133
- Locations
- 🇺🇸
University of California San Diego/Psychiatry, San Diego, California, United States
🇺🇸Sharp Mesa Vista Hospital, San Diego, California, United States
🇺🇸Atlanta Behavioral Research, LLC, Atlanta, Georgia, United States
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
- Conditions
- Interventions
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 226
- Registration Number
- NCT03039192
- Locations
- 🇧🇬
Regional Psychiatric Dispansery, Bulgaria, Bulgaria
🇧🇬UMHAT 'Sveti Georgi'-Plovdiv, Plovdiv, Bulgaria
🇪🇪Tartu University Hospital, Tartu, Estonia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.